View Older Stories
-
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
-
UBS Reiterates Neutral Rating on Moderna (MRNA)
-
Moderna (MRNA) call put ratio 14 calls to 1 put with a focus on May 22 weekly 52, 55 and 57 calls
-
Colorado public health officials investigating hantavirus death not linked to cruise ship cluster - ABC
-
High School student in New York linked to suspected hantavirus case - Local report
-
No Cases Of Hantavirus Infection In The US - CDC
-
Moderna Recognized by TIME as One of the World's Most Impactful Companies
-
FDA Commissioner Marty Makary to step down - Politico
-
WHO expects additional cases of hantavirus, but no wider outbreak seen
-
Bernstein: 'Hantavirus boosting interest in Moderna (MRNA)'
-
1 Hantavirus Suspected Case In Nebraska Is Dual US-UK Citizen - Bloomberg
-
HHS downplays Hantavirus risk amid repatriation efforts
-
Moderna shares jump 8% after U.S. national tests positive for hantavirus
-
Moderna (MRNA) call put ratio 7.4 calls to 1 put amid wide price movement
-
Stocks expected to have increasing option volume: CRCL PBR B CEG SPG HIMS MOS PLUG MNDY ASTS FOXA DELL MRNA
-
Moderna Is Working On Early-stage Hantavirus Vaccines - Bloomberg
-
Moderna flu vaccine shows superior efficacy in phase 3 study
-
Moderna flu vaccine data published in medical journal
-
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
-
Moderna (MRNA) PT Raised to $38 at RBC Capital
-
Moderna (MRNA) PT Raised to $32 at BofA Securities
-
Moderna (MRNA) Misses Q1 EPS by $1.38, Beats on Revenue
-
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
-
Moderna (MRNA) call put ratio 2 calls to 1 put with a focus on May 1 weekly 55 calls into quarter results
-
Moderna (MRNA) call put ratio 1 calls to 1 put with a focus on June options into quarter results
-
Moderna begins phase 3 trial of mRNA bird flu vaccine
-
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
-
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
-
Moderna receives EU approval for first flu-COVID combination vaccine
-
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
-
Moderna to Present at Upcoming Conferences in May 2026
-
Moderna presents melanoma therapy data showing 83% response rate
-
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026
-
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
-
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
Moderna shares jump as settlement removes major legal overhang
-
Moderna (MRNA) call put ratio 2.4 calls to 1 put into resolves litigation
-
Jefferies Reiterates Hold Rating on Moderna (MRNA): "cash breakeven guidance is clearer"
-
After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
-
Moderna settles patent dispute with Arbutus for $950 million
-
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
-
EMA committee recommends approval for Moderna's flu-COVID combo vaccine
-
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influen
-
Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
-
Moderna (MRNA) PT Raised to $69 at Piper Sandler
-
BioNTech sues Moderna for U.S. patent infringement over covid vaccine MNEXspike - Court filing
-
Moderna to Present at Upcoming Conferences in March 2026
-
FDA accepts Moderna flu vaccine application for review
-
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

